Year: 2025

CALGARY, Alberta, Jan. 10, 2025 (GLOBE NEWSWIRE) — Canadian Premium Sand Inc. (“CPS” or the “Company”) (TSXV: CPS) is pleased to announce the conclusion of the previously announced warrant exercise and its fiscal year end 2024 financial results. The Company’s audited financial statements and notes thereto and Management’s Discussion and Analysis for the three months and year ended September 30, 2024, are available under CPS’s SEDAR+ profile. Warrant Exercise and Expiration of all outstanding Warrants Following the Company’s December 16, 2024 announcement regarding exercise of common share purchase warrants (“Warrants”) and extension of the convertible debenture maturity date, the Company is pleased to report that in the month of December, 9,206,404 Warrants were exercised by the Company’s large shareholders, board members and management....

Funding supports the American Red Cross and the Los Angeles Fire Department Foundation NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) — The Verizon Foundation is stepping up to support communities devastated by the Southern California fires and windstorms with a total of $1 million in donations. The contributions aim to provide much-needed aid and resources to support firefighters and the community. The donations include $500K to the American Red Cross and $500K to the Los Angeles Fire Department Foundation (LAFD). The American Red Cross donation will support emergency relief efforts in the LA area. The LA Fire Department Foundation donation will help cover the costs of essential tools and safety equipment for LAFD firefighters, including hydration backpacks, wildland brush tools and emergency fire shelters. “The fires and windstorms...

Geneva, Switzerland, Jan. 10, 2025 (GLOBE NEWSWIRE) — Event to be held on January 22, 2025 in DavosAdditional information and registration can be found at https://www.wisekey.com/davos25/quantumpanel/ SEALSQ Corp (NASDAQ: LAES) (“SEALSQ” or “Company”), a company specializing in Semiconductors, PKI, and Post-Quantum technology hardware and software products, in collaboration with its parent company WISeKey International Holding Ltd (“WISeKey”), to organize a thought-provoking roundtable on January 22, 2025 in Davos focused on “Cybersecurity in a Post-Quantum AI Era: What Happens When You Mix Generative AI with Quantum Computing?” Roundtable DetailsLocation: Morosani Schweizerhof, Promenade 50, 7270 Davos, SwitzerlandDate: Wednesday, January 22, 2025Time: 10:30 am CET – 2:00 pm CETLearn More and Register (use...

BRAINTREE, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT) today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 3,788,550 shares of the Company’s common stock at a purchase price of $2.27 per share of common stock. In addition, in a concurrent private placement, the Company issued unregistered short-term series H preferred investment options. The short-term series H preferred investment options to purchase up to 7,577,100 shares of common stock have an exercise price of $2.10 per share and are immediately exercisable following issuance for a period of two years thereafter. H.C. Wainwright & Co. acted as the exclusive placement agent for the offerings. The gross proceeds to the Company from the offerings...

BOSTON, MASSACHUSETTS, Jan. 10, 2025 (GLOBE NEWSWIRE) — BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral diseases, fibrosis, stroke, dementia, and Alzheimer’s disease, announced its preprint article titled “Immune Checkpoint Inhibitors (ICI): Prospects for Galectin-3 Modulation to Increase Objective Response Rate (ORR) and Remission-free Survival in Oncology Patients” (the “Article”) authored by Dr. Adesuyi Ajayi, Dr. David Platt, and Andrew Blumenthal. The preprint reviews detailed theories regarding the resistance to ICI therapy and how galectin-3 contributes to resistance. Immune Checkpoint Inhibitors (ICI): Prospects for Galectin-3 Modulation to Increase Objective Response Rate (ORR) and Remission-free Survival in Oncology Patientshttp://dx.doi.org/10.13140/RG.2.2.31077.31202...

Company brought new flexibility to meet investor needs and increase liquidity, stability, affordability in multifamily market MCLEAN, Va., Jan. 10, 2025 (GLOBE NEWSWIRE) — Freddie Mac (OTCQB: FMCC) issued $56 billion of securities through its multifamily risk transfer platform in 2024, transferring interest rate risk, liquidity risk and the majority of expected credit risk away from U.S. taxpayers to private investors. A leading issuer of multifamily securities, Freddie Mac Multifamily settled $27.7 billion in K-Deals®, the company’s signature offering, along with $22.1 billion in Multi PC® issuances over the year. In 2024, the company adapted to meet market demands by introducing Giant PCs and multi-sponsor Q-Deals, along with other innovations, and surpassed the milestone of $24 billion in total issuances for its mission-driven...

MINNEAPOLIS, Jan. 10, 2025 (GLOBE NEWSWIRE) — PetVivo Holdings, Inc. (OTCQB: PETV & PETVW) (“PetVivo”), a pioneering biomedical technology company focused on adapting human biotech, medical device and other therapeutic technologies into osteoarthritis and lameness products for commercial sale in the US companion animal and equine markets, announces new distribution partnerships with Vedco Inc. (“Vedco”), and Clipper Distributing, LLC (“Clipper”), both leaders in logistical solutions and supply of products to veterinarians through the channel-of-distribution for veterinarians. Vedco and Clipper distribute to many of the largest national veterinary product distribution entities in the United States, including MWI, Covetrus, Patterson, Midwest Supply and Penn Supply, to just name a few. “Spryng™ with OsteoCushion™...

CORNELIUS, N.C., Jan. 10, 2025 (GLOBE NEWSWIRE) — Alpha Modus Holdings, Inc. (Nasdaq: AMOD) (“Alpha Modus” or the “Company”), is pleased to announce the appointment of Thomas Gallagher as Chief Revenue Officer (CRO) of the Company. In this role, Mr. Gallagher will oversee global revenue generation strategies, scaling operations, and aligning the Company’s sales, marketing, and business development efforts to accelerate growth and deliver robust shareholder returns. Mr. Gallagher brings over two decades of proven leadership in driving revenue growth, strategic expansion, and operational excellence in competitive markets. Most recently, Mr. Gallagher served as Senior Vice President of Services and Solutions at Zones, where he spearheaded transformative strategies that significantly enhanced sales and operational efficiency. Prior...